Group 1 - Tango Therapeutics, Inc. (TNGX) closed at $5.93, with a 26.4% gain over the past four weeks, and a mean price target of $10.43 indicating a 75.9% upside potential [1] - The average of seven short-term price targets ranges from $8.00 to $13.00, with a standard deviation of $2.23, suggesting a potential increase of 34.9% to 119.2% from the current price [2] - Analysts show strong agreement on TNGX's ability to report better earnings than previously predicted, which supports the view of potential upside [4][11] Group 2 - The Zacks Consensus Estimate for TNGX's current year has increased by 1% over the past month, with one estimate going higher and no negative revisions [12] - TNGX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting exact gains, they can indicate the direction of price movement, which appears to be a good guide [14]

Group 1 - Metsera Inc. (MTSR) shares have increased by 6.8% over the past four weeks, closing at $35.32, with a mean price target of $55 indicating a potential upside of 55.7% [1] - The mean estimate includes three short-term price targets with a standard deviation of $14.8, where the lowest estimate is $38.00 (7.6% increase) and the highest is $65.00 (84% increase) [2] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price movements [11][12] Group 2 - The Zacks Consensus Estimate for the current year has risen by 1.9% over the last 30 days, with one estimate moving higher and no negative revisions [12] - MTSR holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting exact gains, they can indicate the direction of price movement [14]

Core Viewpoint - Kimbell Royalty (KRP) shares have increased by 3.9% recently, with a mean price target of $18.6 suggesting a potential upside of 30.7% from the current price of $14.23 [1] Price Targets and Analyst Estimates - The mean estimate consists of five short-term price targets with a standard deviation of $4.98, indicating variability among analysts [2] - The lowest estimate is $12.00, suggesting a 15.7% decline, while the highest estimate is $24.00, indicating a potential increase of 68.7% [2] - Analysts' price targets can often mislead investors, as empirical research shows they rarely indicate actual stock price movements [7][10] Earnings Estimates and Analyst Agreement - Analysts have shown increasing optimism regarding KRP's earnings, with a strong consensus on higher EPS estimates, which correlates with potential stock price increases [11] - Over the past 30 days, one estimate has increased, leading to a 34.4% rise in the Zacks Consensus Estimate for the current year [12] - KRP holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Conclusion on Price Movement - While the consensus price target may not be a reliable measure of KRP's potential gains, the direction indicated by these targets appears to be a useful guide for investors [14]

Group 1 - Omnicom (OMC) shares have increased by 3.2% over the past four weeks, closing at $73.84, with a mean price target of $95.56 indicating a potential upside of 29.4% [1] - The mean estimate consists of nine short-term price targets with a standard deviation of $13.94, where the lowest estimate is $80.00 (8.3% increase) and the highest is $120.00 (62.5% increase) [2] - Analysts show strong agreement on OMC's ability to report better earnings than previously predicted, which supports the view of potential upside [4][11] Group 2 - Recent revisions in earnings estimates have been positive, with one estimate moving higher in the last 30 days, leading to a 0.1% increase in the Zacks Consensus Estimate [12] - OMC holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for upside [13] - While consensus price targets may not be reliable for quantifying gains, they can provide a directional guide for price movement [14]

Core Viewpoint - Vermilion Energy (VET) shares have seen a 1.2% increase over the past four weeks, closing at $7.4, with a potential upside indicated by Wall Street analysts' price targets suggesting a mean estimate of $9.6, representing a 29.7% upside [1] Price Targets and Estimates - The average of 10 short-term price targets ranges from a low of $7.18 to a high of $12.52, with a standard deviation of $1.79, indicating variability among analysts [2] - The lowest estimate suggests a 3% decline from the current price, while the highest estimate indicates a 69.2% upside [2] - Analysts' consensus on price targets is often questioned, as they may not accurately reflect future stock prices [3][7] Earnings Estimates and Analyst Agreement - Analysts are optimistic about VET's earnings prospects, with a strong agreement in revising EPS estimates higher, which correlates with potential stock price increases [4][11] - The Zacks Consensus Estimate for the current year has increased by 9.5% over the past month, with no negative revisions [12] - VET holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Conclusion on Price Movement - While consensus price targets may not be reliable for predicting the extent of VET's gains, they can provide a directional guide for potential price movements [14]

Core Viewpoint - Apogee Enterprises (APOG) shows potential for significant upside, with a mean price target of $54 indicating a 28.2% increase from the current price of $42.11 [1] Price Targets and Analyst Estimates - The mean estimate consists of three short-term price targets with a standard deviation of $9, where the lowest estimate is $45.00 (6.9% increase) and the highest is $63.00 (49.6% increase) [2] - A low standard deviation suggests strong agreement among analysts regarding the stock's price movement, which can be a starting point for further research [9] Earnings Estimates and Analyst Optimism - Analysts have shown growing optimism about APOG's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which correlates with near-term stock price movements [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 2.9%, with one estimate moving higher and no negative revisions [12] Zacks Rank and Investment Potential - APOG currently holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be entirely reliable, the implied direction of price movement appears to be a good guide for potential upside [14]

Core Viewpoint - Summit Therapeutics PLC (SMMT) has seen a 2.8% increase in share price over the past four weeks, closing at $21.2, with a mean price target of $34.56 indicating a potential upside of 63% according to Wall Street analysts [1]. Price Targets and Analyst Estimates - The mean estimate consists of nine short-term price targets with a standard deviation of $10, where the lowest estimate is $12.00 (43.4% decline) and the highest is $44.00 (107.6% increase) [2]. - Analysts' price targets can often mislead investors, as empirical research shows that they rarely indicate the actual price direction of a stock [7]. - A low standard deviation among price targets suggests a high degree of agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9]. Earnings Estimates and Analyst Sentiment - Analysts have shown strong agreement in revising SMMT's earnings estimates higher, which correlates with potential stock price increases [11]. - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 2.1%, with one estimate moving higher and no negative revisions [12]. - SMMT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating a strong potential upside [13]. Conclusion on Price Movement - While the consensus price target may not be a reliable indicator of the extent of SMMT's potential gains, the implied direction of price movement appears to be a useful guide [14].

Group 1 - Manchester United (MANU) shares have increased by 19.7% in the past four weeks, closing at $16.99, with a mean price target of $21.97 indicating a potential upside of 29.3% [1][2] - The average price targets range from a low of $16.90 to a high of $26.00, with a standard deviation of $4.64, suggesting variability in analyst estimates [2][9] - Analysts have shown a strong consensus in revising earnings estimates higher, with the Zacks Consensus Estimate for the current year increasing by 79.9% over the past month [11][12] Group 2 - MANU holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] - The correlation between earnings estimate revisions and near-term stock price movements supports the expectation of an upside in MANU [11][14] - While price targets may not be reliable indicators of actual stock price movements, they can provide a directional guide for potential price changes [10][14]

Core Viewpoint - QXO, Inc. has seen a 21.9% increase in share price over the past four weeks, closing at $20.73, with analysts suggesting a potential upside of 65.6% based on a mean price target of $34.33 [1][11]. Price Targets and Analyst Estimates - The mean price target consists of three short-term estimates with a standard deviation of $8.74, indicating variability among analysts. The lowest estimate is $27.00 (30.3% increase), while the highest is $44.00 (112.3% increase) [2][9]. - Analysts' price targets can often mislead investors, as empirical research shows that they rarely indicate actual stock price movements [7][10]. - A low standard deviation in price targets suggests a strong agreement among analysts regarding the stock's price direction, which can serve as a starting point for further research [9]. Earnings Estimates and Analyst Sentiment - There is growing optimism among analysts regarding QXO's earnings prospects, supported by a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11][12]. - Over the past 30 days, one estimate has increased with no negative revisions, leading to a 425% increase in the Zacks Consensus Estimate for the current year [12]. - QXO holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13]. Conclusion on Price Movement - While the consensus price target may not be a reliable measure of QXO's potential gains, the implied direction of price movement appears to be a useful guide for investors [14].

Group 1 - BILL Holdings (BILL) closed at $45.28, with a 0.2% gain over the past four weeks, and a mean price target of $66.75 indicating a 47.4% upside potential [1] - The mean estimate consists of 24 short-term price targets with a standard deviation of $20.19, where the lowest estimate is $40.00 (11.7% decline) and the highest is $120.00 (165% increase) [2] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price movements [11][12] Group 2 - The Zacks Consensus Estimate for the current year has increased by 0.5% due to one upward revision and no negative revisions in the last 30 days [12] - BILL currently holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of the extent of potential gains, it does suggest a positive direction for price movement [14]